Lisdexamfetamine for Menopause Brain Fog: Four Trial and Label Findings

The natural-menopause study favored daily-function ratings

The 2015 crossover trial¹ enrolled 35 women; 32 completed both four-week periods, taking lisdexamfetamine and placebo in turn, separated by a washout. Eligible ages were 45–60.¹

The primary Brown Attention Deficit Disorder Scale measured reported difficulties with tasks such as organizing work and maintaining focus. Mean total scores were 21.2 on medication versus 29.8 on placebo, from 35.7 at baseline; lower scores indicated fewer difficulties. Delayed paragraph recall also improved significantly, but other cognitive tests did not. Shire and NIH provided funding.¹

The surgical-menopause study tested a different population

The 2024 trial² randomized 69 participants aged 35–58 after preventive removal of the ovaries and fallopian tubes; 57 completed. Participants took medication and placebo in separate six-week periods, with a washout between them.²

Reported difficulties declined an average 39.3% with lisdexamfetamine versus 2.7% with placebo. A demanding attention/working-memory task favored treatment; sustained attention and verbal learning/memory did not. Analyses were not adjusted for multiple comparisons.²

Screening limits who the findings describe

ADHD was excluded in both trials. A favorable response therefore cannot be treated as an ADHD diagnosis. Both studies screened out heart disease and significant blood-pressure problems; the natural-menopause trial also excluded current psychiatric disorders and regular psychotropic medication use.¹²

The surgical-menopause sample was 95% White. More side effects occurred with medication, potentially revealing treatment assignment. This short trial cannot establish long-term benefit.²

The current US label requires a separate risk discussion

Vyvanse is approved for ADHD and moderate-to-severe binge-eating disorder in adults, not menopause-related thinking difficulties. It is a Schedule II controlled stimulant with a boxed warning about abuse, misuse and addiction; misuse can cause overdose and death.³

The label calls for cardiac assessment and blood-pressure/pulse monitoring. It warns about psychiatric effects and serotonin syndrome with serotonergic medicines, including some antidepressants. MAO inhibitors, including use within the preceding 14 days, are contraindicated. A prescriber needs the full medicine list and relevant medical history.³

Prepare a visit around the task you are struggling with

Write down a recent example: losing your place while preparing invoices, forgetting instructions midway through a task or repeatedly missing an appointment. Add when it started, whether it is worsening and what else changed that month. Bring the paper rather than relying on remembering everything in the room.

Ask: “What should we assess before attributing this to menopause, and what benefit and follow-up would justify any treatment?”

“The Visit Brief” in My Body Changed. Now What? organizes your stage, three priority changes and their impact, previous attempts, history and questions on one page. Our general menopause brain-fog guide covers the broader assessment question.